First National Bank Sioux Falls Has $426,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

First National Bank Sioux Falls lowered its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 8.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,318 shares of the biopharmaceutical company’s stock after selling 750 shares during the period. First National Bank Sioux Falls’ holdings in Pfizer were worth $426,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. RB Capital Management LLC boosted its position in shares of Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 341 shares during the period. Ironwood Wealth Management LLC. raised its stake in Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after purchasing an additional 400 shares in the last quarter. United Bank boosted its holdings in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares during the period. Ergoteles LLC grew its position in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp increased its holdings in shares of Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the period. 67.62% of the stock is owned by institutional investors.

Get Pfizer alerts:

Pfizer Price Performance

Shares of NYSE:PFE opened at $41.50 on Monday. The firm has a market cap of $234.24 billion, a PE ratio of 7.57, a price-to-earnings-growth ratio of 1.40 and a beta of 0.64. Pfizer Inc. has a 52 week low of $39.23 and a 52 week high of $56.32. The firm’s fifty day moving average is $41.66 and its 200-day moving average is $45.47. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22.

Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, topping the consensus estimate of $1.03 by $0.11. The firm had revenue of $24.30 billion for the quarter, compared to the consensus estimate of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.08 EPS. Sell-side analysts predict that Pfizer Inc. will post 3.3 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. SVB Leerink reduced their target price on Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a report on Wednesday, February 1st. StockNews.com began coverage on shares of Pfizer in a report on Thursday, March 16th. They issued a “buy” rating on the stock. Barclays cut their price target on shares of Pfizer from $49.00 to $44.00 and set an “equal weight” rating for the company in a report on Wednesday, February 1st. UBS Group set a $45.00 price objective on shares of Pfizer in a research note on Tuesday, March 14th. Finally, Morgan Stanley cut their target price on Pfizer from $53.00 to $45.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 1st. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $49.93.

Insider Buying and Selling at Pfizer

In other news, major shareholder Pfizer Inc acquired 1,811,594 shares of Pfizer stock in a transaction dated Friday, March 17th. The shares were bought at an average cost of $2.76 per share, with a total value of $4,999,999.44. Following the purchase, the insider now owns 5,952,263 shares in the company, valued at approximately $16,428,245.88. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.05% of the company’s stock.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Recommended Stories

• Get a free copy of the StockNews.com research report on Pfizer (PFE)
• Novartis Shares Leap On Positive Clinical Trial Data
• MarketBeat Week in Review – 4/3 – 4/7
• Costco Sales Disappoint, Markets Are Missing This Upside Driver
• First Republic Bank Is A Speculative Play, Here’s Why
• The WD-40 Company Bottoms With Reversal In Sight 

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.